MX2024007665A - Metodos de tratamiento de tumores cerebrales y neuroblastomas. - Google Patents
Metodos de tratamiento de tumores cerebrales y neuroblastomas.Info
- Publication number
- MX2024007665A MX2024007665A MX2024007665A MX2024007665A MX2024007665A MX 2024007665 A MX2024007665 A MX 2024007665A MX 2024007665 A MX2024007665 A MX 2024007665A MX 2024007665 A MX2024007665 A MX 2024007665A MX 2024007665 A MX2024007665 A MX 2024007665A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- neuroblastomas
- treating brain
- brain tumours
- patient
- Prior art date
Links
- 208000003174 Brain Neoplasms Diseases 0.000 title abstract 2
- 206010029260 Neuroblastoma Diseases 0.000 title abstract 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente divulgación se refiere a métodos para tratar un tumor cerebral o un neuroblastoma en un paciente en necesidad de esto, el método que comprende administrar al paciente una cantidad terapéuticamente efectiva de compuestos de azaquinolona sustituidos que tienen actividad como un inhibidor de poli(ADP-ribosa) polimerasa (PARP).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163292029P | 2021-12-21 | 2021-12-21 | |
| PCT/EP2022/086913 WO2023118085A1 (en) | 2021-12-21 | 2022-12-20 | Methods of treating brain tumours and neuroblastomas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007665A true MX2024007665A (es) | 2024-07-09 |
Family
ID=84980901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007665A MX2024007665A (es) | 2021-12-21 | 2022-12-20 | Metodos de tratamiento de tumores cerebrales y neuroblastomas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250082630A1 (es) |
| EP (1) | EP4452256A1 (es) |
| JP (1) | JP2025503465A (es) |
| KR (1) | KR20240127394A (es) |
| CN (1) | CN118317793A (es) |
| AU (1) | AU2022422276A1 (es) |
| CA (1) | CA3242082A1 (es) |
| IL (1) | IL313661A (es) |
| MX (1) | MX2024007665A (es) |
| TW (1) | TW202342037A (es) |
| WO (1) | WO2023118085A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
| AU2023275808A1 (en) * | 2022-05-25 | 2024-12-12 | Xizang Haisco Pharmaceutical Co., Ltd. | Bicyclic derivative parp inhibitor and use thereof |
| JP2025519219A (ja) * | 2022-06-02 | 2025-06-24 | チュヨンドゥ イーストン バイオファーマシューティカルズ カンパニー リミテッド | アザキノリノン誘導体、その調製方法及びその使用 |
| WO2025120513A1 (en) * | 2023-12-05 | 2025-06-12 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ291624A (en) | 1994-08-12 | 1998-07-28 | Myriad Genetics Inc | Method of diagnosis of a predisposition to breast cancer |
| DK0705903T3 (da) | 1994-08-12 | 2001-08-27 | Myriad Genetics Inc | Mutationer i det 17q-koblede bryst- og ovariecancerprædisponeringen |
| GB2415430B (en) | 2003-03-12 | 2006-07-12 | Kudos Pharm Ltd | Phthalazinone derivatives |
| TWI837403B (zh) * | 2019-07-19 | 2024-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| US11795158B2 (en) * | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
-
2022
- 2022-12-20 IL IL313661A patent/IL313661A/en unknown
- 2022-12-20 US US18/721,997 patent/US20250082630A1/en active Pending
- 2022-12-20 AU AU2022422276A patent/AU2022422276A1/en active Pending
- 2022-12-20 MX MX2024007665A patent/MX2024007665A/es unknown
- 2022-12-20 JP JP2024536513A patent/JP2025503465A/ja active Pending
- 2022-12-20 WO PCT/EP2022/086913 patent/WO2023118085A1/en active Application Filing
- 2022-12-20 KR KR1020247024081A patent/KR20240127394A/ko active Pending
- 2022-12-20 CN CN202280077926.3A patent/CN118317793A/zh active Pending
- 2022-12-20 CA CA3242082A patent/CA3242082A1/en active Pending
- 2022-12-20 EP EP22843653.1A patent/EP4452256A1/en active Pending
- 2022-12-21 TW TW111149137A patent/TW202342037A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL313661A (en) | 2024-08-01 |
| KR20240127394A (ko) | 2024-08-22 |
| US20250082630A1 (en) | 2025-03-13 |
| WO2023118085A1 (en) | 2023-06-29 |
| JP2025503465A (ja) | 2025-02-04 |
| AU2022422276A1 (en) | 2024-08-01 |
| TW202342037A (zh) | 2023-11-01 |
| EP4452256A1 (en) | 2024-10-30 |
| CA3242082A1 (en) | 2023-06-29 |
| CN118317793A (zh) | 2024-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024007665A (es) | Metodos de tratamiento de tumores cerebrales y neuroblastomas. | |
| MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
| CL2021002533A1 (es) | Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras | |
| CR20120638A (es) | Métodos de terapia combinada para tratar enfermedades proliferativas | |
| MX392869B (es) | Kit para el tratamiento o alivio de dolor en el sitio de incision despues de un procedimiento quirurgico | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| BR112021018591A2 (pt) | Compostos e usos dos mesmos | |
| ECSP19014247A (es) | Formas de dosificación para tratar y prevenir trastornos del sueño | |
| MX2018012165A (es) | Metodos de tratamiento de canceres pediatricos. | |
| ECSP21034596A (es) | 2,3,5-trimetil-6-nonilclohexa-2,5-diena-1,4-diona para suprimir y tratar alfa-sinucleinopatías, tauopatías y otros trastornos | |
| CL2023000289A1 (es) | Combinaciones para el tratamiento de cáncer | |
| MX2024007673A (es) | Inhibidores de poli adp-ribosa polimerasas (parp1). | |
| PH12020550821A1 (en) | Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration | |
| MX2021010173A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso. | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| MX2024008461A (es) | Metodos para tratar trastornos linfoproliferativos malignos. | |
| BR112022000231A2 (pt) | Novos métodos | |
| MX392030B (es) | Agentes y usos de los mismos para prevenir y/o tratar enfermedades neurológicas | |
| UY30158A1 (es) | Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
| WO2005123660A3 (en) | Polycationic compounds and uses thereof | |
| CL2020002317A1 (es) | Compuesto inhibidor de tirosina quinasa c-abl: modalidades y métodos de fabricación y uso | |
| MX2018004286A (es) | Metodos de tratamiento de lesiones o condiciones relacionadas con el edema del sistema nervioso central. | |
| CL2024000867A1 (es) | Compuestos de imidazopiridazina inhibidores de il-17. | |
| MX2021008903A (es) | Compuestos y usos de los mismos. | |
| CL2022000781A1 (es) | Tratamientos cognitivos medicinales |